Pharmather Holdings Stock Net Asset
PHRRF Stock | USD 0.34 0.01 3.03% |
Fundamental analysis of Pharmather Holdings allows traders to better anticipate movements in Pharmather Holdings' stock price by examining its financial health and performance throughout various phases of its business cycle.
Pharmather |
Pharmather Holdings OTC Stock Net Asset Analysis
Pharmather Holdings' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Pharmather Holdings Net Asset | 12.16 M |
Most of Pharmather Holdings' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmather Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
Based on the recorded statements, Pharmather Holdings has a Net Asset of 12.16 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
Pharmather Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmather Holdings' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Pharmather Holdings could also be used in its relative valuation, which is a method of valuing Pharmather Holdings by comparing valuation metrics of similar companies.Pharmather Holdings is currently under evaluation in net asset category among its peers.
Pharmather Fundamentals
Return On Equity | -0.63 | |||
Return On Asset | -0.25 | |||
Current Valuation | (3.24 M) | |||
Shares Outstanding | 88.17 M | |||
Shares Owned By Insiders | 18.67 % | |||
Shares Owned By Institutions | 0.06 % | |||
Price To Earning | 2.26 X | |||
Price To Book | 0.57 X | |||
EBITDA | (4.1 M) | |||
Net Income | (4.01 M) | |||
Cash And Equivalents | 10.15 M | |||
Cash Per Share | 0.12 X | |||
Current Ratio | 70.26 X | |||
Book Value Per Share | 0.09 X | |||
Cash Flow From Operations | (3.51 M) | |||
Earnings Per Share | (0.04) X | |||
Beta | 2.98 | |||
Market Capitalization | 13.44 M | |||
Total Asset | 12.16 M | |||
Net Asset | 12.16 M |
About Pharmather Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmather Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmather Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmather Holdings based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
VALE | Vale SA ADR | |
EGY | Vaalco Energy | |
CMCSA | Comcast Corp | |
BTE | Baytex Energy Corp | |
SOXS | Direxion Daily Semiconductor |
Other Information on Investing in Pharmather OTC Stock
Pharmather Holdings financial ratios help investors to determine whether Pharmather OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmather with respect to the benefits of owning Pharmather Holdings security.